Abstract Peripartum Cardiomyopathy (PPCM) is an idiopathic cardiomyopathy condition characterised by LV systolic dysfunction with LVEF < 45% occurring during last months of pregnancy to early postpartum phase. After initial case description by Demakis et al understanding of PPCM pathophysiology, it’s genetic determinants and management approaches have undergone major changes. A vasculo-hormonal model has been proposed to explain the cardiomyocyte damage caused by modified maternal prolactin hormone. Though rapid recovery of LV function is common, in a minority of cases it can result in refractory heart failure and cardiogenic shock. Recently described ESC EORP PPCM recovery score is quite useful in predicting LV function recovery. Oral bromocriptine therapy is a disease modifying therapy for PPCM that improves LV function by suppressing prolactin levels. Its role is being tested in larger clinical trials. Recently proposed BOARD scheme advocates use of multimodal treatment to reduce cardiovascular outcomes in patients with severe LV dysfunction. Vaginal delivery and breast feeding are to be encouraged to improve feto-maternal outcomes. LV function recovery during index PPCM case is the single most important factor that determines recurrence and outcome of PPCM in subsequent pregnancies.